223 related articles for article (PubMed ID: 7511144)
1. Binding and activation of plasminogen on the surface of osteosarcoma cells.
Campbell PG; Wines K; Yanosick TB; Novak JF
J Cell Physiol; 1994 Apr; 159(1):1-10. PubMed ID: 7511144
[TBL] [Abstract][Full Text] [Related]
2. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
4. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
5. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
6. Modulation of cell-associated plasminogen activation by stromelysin-1 (MMP-3).
Ugwu F; Lemmens G; Collen D; Lijnen HR
Thromb Haemost; 1999 Sep; 82(3):1127-31. PubMed ID: 10494776
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines.
Niedbala MJ; Sartorelli AC
Cancer Commun; 1990; 2(5):189-99. PubMed ID: 2142433
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line.
Karikó K; Kuo A; Boyd D; Okada SS; Cines DB; Barnathan ES
Cancer Res; 1993 Jul; 53(13):3109-17. PubMed ID: 8391387
[TBL] [Abstract][Full Text] [Related]
9. Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen.
Ellis V; Whawell SA; Werner F; Deadman JJ
Biochemistry; 1999 Jan; 38(2):651-9. PubMed ID: 9888805
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
[TBL] [Abstract][Full Text] [Related]
11. THP-1 macrophage membrane-bound plasmin activity is up-regulated by transforming growth factor-beta 1 via increased expression of urokinase and the urokinase receptor.
Falcone DJ; McCaffrey TA; Mathew J; McAdam K; Borth W
J Cell Physiol; 1995 Aug; 164(2):334-43. PubMed ID: 7622580
[TBL] [Abstract][Full Text] [Related]
12. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
Mazzieri R; Masiero L; Zanetta L; Monea S; Onisto M; Garbisa S; Mignatti P
EMBO J; 1997 May; 16(9):2319-32. PubMed ID: 9171346
[TBL] [Abstract][Full Text] [Related]
13. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
14. Binding and activation of plasminogen at the surface of human keratinocytes.
Reinartz J; Batrla R; Boukamp P; Fusenig N; Kramer MD
Exp Cell Res; 1993 Sep; 208(1):197-208. PubMed ID: 8359216
[TBL] [Abstract][Full Text] [Related]
15. Surface-associated plasminogen activation in leukemic cells: interaction with extracellular matrix.
Martínez J; Santibañez JF
Eur J Cell Biol; 1994 Aug; 64(2):257-63. PubMed ID: 7813513
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen carbohydrate side chains in receptor binding and enzyme activation: a study of C6 glioma cells and primary cultures of rat hepatocytes.
Hall SW; VandenBerg SR; Gonias SL
J Cell Biochem; 1990 Jul; 43(3):213-27. PubMed ID: 1696276
[TBL] [Abstract][Full Text] [Related]
17. The receptor for urokinase-type plasminogen activator of a human keratinocyte line (HaCaT).
Reinartz J; Link J; Todd RF; Kramer MD
Exp Cell Res; 1994 Oct; 214(2):486-98. PubMed ID: 7925643
[TBL] [Abstract][Full Text] [Related]
18. Plasmin modulators, aprotinin and anti-catalytic plasmin antibody, efficiently inhibit destruction of bovine vascular endothelial cells by choriocarcinoma cells.
Sugimura M; Kobayashi H; Terao T
Gynecol Oncol; 1994 Mar; 52(3):337-46. PubMed ID: 7512520
[TBL] [Abstract][Full Text] [Related]
19. Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.
Pass J; Jögi A; Lund IK; Rønø B; Rasch MG; Gårdsvoll H; Lund LR; Ploug M; Rømer J; Danø K; Høyer-Hansen G
Thromb Haemost; 2007 Jun; 97(6):1013-22. PubMed ID: 17549305
[TBL] [Abstract][Full Text] [Related]
20. The topology of plasminogen binding and activation on the surface of human breast cancer cells.
Andronicos NM; Ranson M
Br J Cancer; 2001 Sep; 85(6):909-16. PubMed ID: 11556845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
